Cargando…
Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I
Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agent...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958392/ https://www.ncbi.nlm.nih.gov/pubmed/31658729 http://dx.doi.org/10.3390/ph12040152 |
_version_ | 1783487403113054208 |
---|---|
author | Vieira, Raquel Souto, Selma B. Sánchez-López, Elena López Machado, Ana Severino, Patricia Jose, Sajan Santini, Antonello Fortuna, Ana García, Maria Luisa Silva, Amelia M. Souto, Eliana B. |
author_facet | Vieira, Raquel Souto, Selma B. Sánchez-López, Elena López Machado, Ana Severino, Patricia Jose, Sajan Santini, Antonello Fortuna, Ana García, Maria Luisa Silva, Amelia M. Souto, Eliana B. |
author_sort | Vieira, Raquel |
collection | PubMed |
description | Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed. |
format | Online Article Text |
id | pubmed-6958392 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69583922020-01-23 Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I Vieira, Raquel Souto, Selma B. Sánchez-López, Elena López Machado, Ana Severino, Patricia Jose, Sajan Santini, Antonello Fortuna, Ana García, Maria Luisa Silva, Amelia M. Souto, Eliana B. Pharmaceuticals (Basel) Review Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed. MDPI 2019-10-10 /pmc/articles/PMC6958392/ /pubmed/31658729 http://dx.doi.org/10.3390/ph12040152 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Vieira, Raquel Souto, Selma B. Sánchez-López, Elena López Machado, Ana Severino, Patricia Jose, Sajan Santini, Antonello Fortuna, Ana García, Maria Luisa Silva, Amelia M. Souto, Eliana B. Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I |
title | Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I |
title_full | Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I |
title_fullStr | Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I |
title_full_unstemmed | Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I |
title_short | Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic Syndrome—Review of Classical and New Compounds: Part-I |
title_sort | sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndrome—review of classical and new compounds: part-i |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958392/ https://www.ncbi.nlm.nih.gov/pubmed/31658729 http://dx.doi.org/10.3390/ph12040152 |
work_keys_str_mv | AT vieiraraquel sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti AT soutoselmab sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti AT sanchezlopezelena sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti AT lopezmachadoana sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti AT severinopatricia sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti AT josesajan sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti AT santiniantonello sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti AT fortunaana sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti AT garciamarialuisa sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti AT silvaameliam sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti AT soutoelianab sugarloweringdrugsfortype2diabetesmellitusandmetabolicsyndromereviewofclassicalandnewcompoundsparti |